Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis

Jpn J Clin Oncol. 2019 Oct 1;49(10):924-931. doi: 10.1093/jjco/hyz099.

Abstract

Objectives: Both haplo-identical transplant (haplo) and umbilical cord transplant (UC) are valuable graft options for patients without available matched relative. Previous studies showed inconsistent outcomes comparing Post transplant Cyclophosphamide based haplo (PTCy-haplo) and UC; therefore, we attempt to compare the studies by mean of meta-analysis.

Methods: We searched for titles of articles in MEDLINE (PubMed), Cochrane library, EMBASE database and Google scholar that compared transplantation with PTCy-haplo versus UC. We conducted a random-effect meta-analysis of seven studies involving a total of 3434 participants and reported the pooled odd ratios (OR) of acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), relapse and overall survival (OS) between PTCy-haplo and UC groups.

Results: We found a significantly decreased risk of aGVHD and relapse in the PTCy-haplo group compared to the UC group with a pooled OR of 0.78, 95% Confidence Interval (CI) 0.67-0.92, I2=0%, and 0.74, 95% CI 0.57-0.97, I2=23.9% respectively. We also found a significantly increased rate of cGVHD and OS with a pooled OR of 1.41, 95% CI 1.02-1.95, I2=56.8%, and 1.77, 95% CI 1.1-2.87, I2=82.5%, respectively.

Conclusion: Our meta-analysis of clinical trials demonstrated superior outcome from PTCy-haplo group compared to the UC group in terms of decreased rate of aGVHD and relapse as well as the increased rate of OS but inferior in terms of increased cGVHD risk compared to UC transplant.

Keywords: Post transplant cyclophosphamide based haplo-identical transplant; acute graft-versus-host disease; chronic graft-versus-host disease; hematologic malignancy; overall survival and outcome; relapse; umbilical cord blood transplant.

Publication types

  • Meta-Analysis

MeSH terms

  • Adult
  • Cord Blood Stem Cell Transplantation*
  • Cyclophosphamide / therapeutic use*
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Middle Aged
  • Transplantation, Haploidentical*

Substances

  • Cyclophosphamide